Newcastle disease virus co-expressing interleukin 7 and interleukin 15 modified tumor cells as a vaccine for cancer immunotherapy

Cancer Science

Volumn 109, Issue 2, 2018, Pages 279-288

  Xu, Xiaojing ^a   Sun, Qing ^b,c   Mei, Yu ^d   Liu, Yonghao ^e   Zhao, Lixiang ^a  

^a MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

^b YANGZHOU UNIVERSITY   (China)

^c UNIVERSITY OF OTAGO   (New Zealand)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

interleukin 15; Interleukin 7; Newcastle disease virus; tumor; vaccine

Indexed keywords

INTERLEUKIN 15; INTERLEUKIN 7; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOTOXICITY; CYTOTOXICITY ASSAY; FEMALE; IN VITRO STUDY; MOUSE; NEWCASTLE DISEASE VIRUS; NONHUMAN; PRIORITY JOURNAL; REVERSE GENETICS; THERAPY EFFECT; TUMOR IMMUNITY; TUMOR VOLUME; VIRUS RECOMBINANT; ADMINISTRATION AND DOSAGE; ANIMAL; CELL PROLIFERATION; CELL SURVIVAL; EXPERIMENTAL MELANOMA; GENE VECTOR; GENETICS; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; TUMOR CELL LINE;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; GENETIC VECTORS; IMMUNOTHERAPY; INTERLEUKIN-15; INTERLEUKIN-7; MELANOMA, EXPERIMENTAL; MICE; NEWCASTLE DISEASE VIRUS; REVERSE GENETICS;

EID: 85040192359     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.13468     Document Type: Article

References (28)

1. de Leeuw O, Peeters B. Complete nucleotide sequence of Newcastle disease virus: evidence for the existence of a new genus within the subfamily Paramyxovirinae. J Gen Virol. 1999;80(Pt 1):131-136.
2. Krishnamurthy S, Samal SK. Nucleotide sequences of the trailer, nucleocapsid protein gene and intergenic regions of Newcastle disease virus strain Beaudette C and completion of the entire genome sequence. J Gen Virol. 1998;79(Pt 10):2419-2424.
3. Ganarc K, Das M, Sinha S, Kumar S. Newcastle disease virus: current status and our understanding. Virus Res. 2014;184:71-81.
4. Csatary LK. Viruses in the treatment of cancer. Lancet. 1971;2:825.
5. Lorence RM, Katubig BB, Reichard KW, et al. Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy. Cancer Res. 1994;54:6017-6021.
6. Lorence RM, Reichard KW, Katubig BB, et al. Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy. J Natl Cancer Inst. 1994;86:1228-1233.
7. Reichard KW, Lorence RM, Cascino CJ, et al. Newcastle disease virus selectively kills human tumor cells. J Surg Res. 1992;52:448-453.
8. Schirrmacher V, Fournier P. Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer. Methods Mol Biol. 2009;542:565-605.
9. Sinkovics JG, Horvath JC. Newcastle disease virus (NDV): brief history of its oncolytic strains. J Clin Virol. 2000;16:1-15.
10. Ni J, Schirrmacher V, Fournier P. The hemagglutinin-neuraminidase gene of Newcastle Disease Virus: a powerful molecular adjuvant for DNA anti-tumor vaccination. Vaccine. 2010;28:6891-6900.
11. Ramezanpour B, Haan I, Osterhaus A, Claassen E. Vector-based genetically modified vaccines: exploiting Jenner's legacy. Vaccine. 2016;34:6436-6448.
12. Janke M, Peeters B, Zhao H, et al. Activation of human T cells by a tumorvaccine infected with recombinant Newcastle disease virus producing IL-2. Int J Oncol. 2008;33:823-832.
13. Zhao L, Mei Y, Sun Q, et al. Autologous tumor vaccine modified with recombinant new castle disease virusexpressing IL-7 promotes antitumor immune response. J Immunol. 2014;193:735-745.
14. Janke M, Peeters B, de Leeuw O, et al. Recombinant Newcastle disease virus (NDV) withinserted gene coding for GM-CSF as a new vector for cancer immunogenetherapy. Gene Ther. 2007;14:1639-1649.
15. Schirrmacher V, Heicappell R. Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. II. Establishment of specific systemic anti-tumor immunity. Clin Exp Metastasis. 1987;5:147-156.
16. Lin J, Zhu Z, Xiao H, et al. The role of IL-7 in immunity and cancer. Anticancer Res. 2017;37:963-967.
17. Rhode PR, Egan JO, Xu W, et al. Comparison of the superagonist complex, ALT-803, to IL15 as cancer immunotherapeutics in animal Models. Cancer Immunol Res. 2016;4:49-60.
18. + T cells and IL15 resistance. Cancer Immunol Res. 2016;4:799-811.
19. Van den Bergh JMJ, Smits ELJM, Berneman ZN, et al. Monocyte-derived dendritic cells with silenced ligands and transpresenting interleukin-15 stimulate tumor-reactive T-cell expansion. Cancer Immunol Res. 2017;5:710-715.
20. Cieri N, Camisa B, Cocchiarella F, Forcato M, et al. IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood. 2013;121:573-584.
21. Sun Q, Zhao L, Song Q, et al. Hybrid- and complex-type N-glycans are not essential for Newcastle disease virus infection and fusion of host cells. Glycobiology. 2012;22:369-378.
22. Altomonte J, Marozin S, Schmid RM, Ebert O. Engineered newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma. Mol Ther. 2010;18:275-284.
23. Phuangsab A, Lorence RM, Reichard KW, Peeples ME, Walter RJ. Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration. Cancer Lett. 2001;172:27-36.
24. Kaech SM, Tan JT, Wherry EJ, Konieczny BT, Surh CD, Ahmed R. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat Immunol. 2003;4:1191-1198.
25. Schluns KS, Williams K, Ma A, Zheng XX, Lefrancois L. Cutting edge: requirement for IL-15 in the generation of primary and memory antigen-specific CD8 T cells. J Immunol. 2002;168:4827-4831.
26. + T cell response against an obligate intracellular parasite. Microbes Infect. 2012;14(13):1160-1168.
27. Cha E, Graham L, Manjili MH, Bear HD. IL-7 + IL-15 are superior to IL-2 for the ex vivo expansion of 4T1 mammary carcinoma-specific T cells with greater efficacy against tumors in vivo. Breast Cancer Res Treat. 2010;122:359-369.
28. Xu X, Sun Q, Yu X, Zhao L. Rescue of nonlytic Newcastle disease virus (NDV) expressing IL-15 for cancer immunotherapy. Virus Res 2017;233:35-41.